YSYu. P. Sych

Yu. P. Sych

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yu. P. Sych has a total of 128 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Classification of Ultrasound Features of Superficially Located Lymph Nodes

    by E. P. Fisenko, G. F. Allahverdieva, M. N. Bulanov, E. A. Busko, N. N. Vetsheva, O. V. Vozgoment, V. E. Gagonova, T. Yu. Danzanova, N. V. Zabolotskaya, A. N. Katrich, et al.

    Assessment of lymphatic drainage areas is a critical task in ultrasound (US) examination of organs and tissues involved in various pathological processes. Superficially located lymph nodes (LNs) are more accessible for US evaluation. The numerous LN changes identified in ultrasound often are challenging for interpretation. The proposed classification provides grading of the detected ultrasound features in superficial LNs into groups, facilitating a risk stratification system for LN malignancy. Objective. To stratify LN ultrasound features according to the degree of deviation from the normal pattern – from loss of benign features to appearance of signs of malignancy – and to establish a classification of changes in superficially located LN based on US findings. Results. The classification comprises six levels: normal/unchanged LNs; probably benign LN changes; indeterminate/uncertain LN changes; suspicious LN changes; highly suspicious LN changes; morphologically confirmed malignant LN. Conclusion. The presented Russian classification for risk stratification of malignancy in superficial LNs will enable a more accurate US assessment of superficial lymph nodes, allowing identification of distinct types of ultrasound structure and selection of suspicious lymph nodes for biopsy.

  • Open Access

    Ultrasound findings and tumors of thyroid after head and neck irradiation

    by I. I. Amergulov, M. G. Pavlova, Yu. P. Sych, V. M. Sotnikov, E. Yu. Kandakova, O. S. Regentova, A. E. Rudneva

    Introduction. Thyroid nodules including thyroid cancer are among the common long-term effects of radiation therapy (RT) to the head and neck region administered for primary central nervous system (CNS) tumors and lymphomas. Aim. To evaluate the frequency and different types of nodules and benign and malignant lesions in thyroid after head and neck irradiation for primary CNS tumors and lymphomas. Mat erials and methods. Patients included in the retrospective trial were divided into 6 groups: group 1 – craniospinal irradiation (CSI) for primary CNS tumors under the age of 18 years, group 2 – CSI for primary CNS tumors above the age of 18 years, group 3 – RT to the neck region for lymphoma treatment in patients under the age of 18 years, group 4 – RT to the neck region for lymphoma treatment in patients above the age of 18 years, group 5 – control for patients irradiated before 18 years, group 6 – control for patients irradiated over the age of 18 years. Results. Thyroid nodules were more common after neck irradiation for lymphoma comparing to CSI (47.1% vs 27%) (p = 0.032). Control groups had even lower nodules rates (p = 0.04). EU-TIRADS 3 were more common after neck irradiation for lympho ma than after CSI (p = 0.013). Female patients developed thyroid nodules more frequently than male (p = 0.001), especially EU-TIRADS 3 and EU-TIRADS 4 (p = 0.027). Furthermore thyroid volume was decreased in patients after irradiation comparing to control groups (p < 0.001). Conclusions. Thyroid nodules are more common in head and neck irradiation than in general population. As there is a risk of cancer in thyroid nodules, thyroid ultrasound must be performed in patients with irradiation in history. It can help to detect serious lesions and provide appropriate treatment if it needs in time.

  • Immune-related thyroid dysfunction and survival in patients treated with immune checkpoint inhibitors: a multicenter prospective cohort study

    by K. Yu. Zherebchikova, E. V. Poddubskaya, A. P. Bondarenko, A. A. Vilenskiy, Yu. P. Sych, V. V. Fadeev

    Aim . To assess the association between immune-related thyroid dysfunction (irTD) and overall survival or progressionfree survival in patients with malignant neoplasms receiving immune checkpoint inhibitor therapy. Materials and methods . This multicenter prospective cohort study comprised 235 patients (156 men; mean age approximately 60 years) with histologically or cytologically confirmed malignancies of various localizations who were treated with programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors. Thyroid function was assessed before the treatment and every 4 weeks thereafter. irTD was diagnosed based on standardized biochemical and ultrasound criteria. Adverse events were graded according to CTCAE (Common Terminology Criteria for Adverse Events). Survival was analyzed using the Kaplan–Meier method, with comparisons performed using the log-rank test, and univariable Cox proportional hazards models, with hazard ratios (HRs) and 95% confidence intervals (CIs), were applied. Results . irTD occurred in 52 patients (22.1%). In all cases, destructive thyroiditis with a transient thyrotoxic phase followed by hypothyroidism (CTCAE grade 1–2) was observed and did not require discontinuation of immune checkpoint inhibitors. The median time to irTD onset was 7.9 weeks. Patients with and without irTD were comparable in terms of sex, age, disease stage, previous cancer therapy, and type of PD-1/PD-L1 inhibitors. The development of irTD was associated with better progression-free survival (median 126.2 vs 40.0 weeks; HR 0.37; 95% CI: 0.25–0.55; p < 0.001) and better overall survival (211.6 vs 147.0 weeks; HR 0.43; 95% CI: 0.25–0.73; p = 0.002). Conclusion. In this prospective multicenter cohort study, irTD occurred in approximately one-fifth of patients treated with PD-1/PD-L1 inhibitors, mainly during the first weeks of therapy, was generally mild, and was associated with improved survival. These findings suggest that irTD may be considered as a potential surrogate marker of treatment efficacy and support the need for regular monitoring of thyroid function during immunotherapy.

  • Open Access

    Assessment of inter-expert agreement among ultrasound diagnostic physicians using the Russian classification of lymphatic nodules ultrasound characteristics LN-RADS

    by Yu. P. Sych, E. Р. Fisenko, A. N. Katrich, M. N. Bulanov

    In the last decade, much attention has been paid to the development of objective criteria for assessing the results of visualization studies in medicine, allowing to minimize diagnostic errors and facilitate the interaction of doctors of different specialties. To assess the condition of the lymph nodes, a scale for the stratification of ultrasound signs LN-RADS has been proposed. Purpose: assessment of the reproducibility of the results of using the LN-RADS scale for stratification of ultrasound signs of lymph nodes and assessment of the consistency of decisions of ultrasound diagnostic doctors who used this classification. Materials and methods . To assess an inter-rater agreement for LN-RADS scale, sixteen experienced specialists in ultrasound independently assessed fifty ultrasound images of the lymphatic nodes with various benign and malignant changes. Results. The inter-rater agreement in utilisation of the LN-RADS scale was moderate, reaching a significant level when assessing malignant changes in the lymph nodes. Conclusions. The LN-RADS stratification system allows for the detection of malignant changes with fairly good reproducibility, which is especially important from a diagnostic point of view.


  • Structural and functional changes in the thyroid gland in the early and late periods after radiation therapy

    by I.I. Amergulov Amergulov, M.G. Pavlova Pavlova, Yu.P. Sych Sych, Yu.R. Zhuravleva Zhuravleva, M.M. Dolov Dolov, M.T. Berdyklychev Berdyklychev, V.Z. Dobrokhotova Dobrokhotova, E.O. Sannikova Sannikova, O.P. Trofimova Trofimova, M.V. Orlova Orlova, et al.

  • Open Access

    Corrigendum: Adaptation of The Diabetes Distress Scale on a Russian-speaking sample of patients with type 1 and type 2 diabetes mellitus (Diabetes mellitus. – 2024. – Т. 27. – №5. https://doi.org/10.14341/DM13150)

    by N. V. Likhodey, V. E. Epishin, M. F. Kalashnikova, A. M. Kaurova, M. V. Tulupova, Yu. P. Sych, I. B. Bondareva

    A corrigendum on «Adaptation of The Diabetes Distress Scale on a Russian-speaking sample of patients with type 1 and type 2 diabetes mellitus» authored by Natalia V. Likhodey, Vitalii E. Epishin, Marina F. Kalashnikova, Aleksandra M. Kaurova, Margarita V. Tulupova, Yulia P. Sych, Irina B. Bondareva (2024). Diabetes Mellitus. 27(5). https://doi.org/10.14341/DM13150.An error was made in the article. In the final version of the article, the order of questions in Figure 1 and Table 4 does not correspond to the version of the questionnaire used during data collection. This discrepancy occurred because two English versions of the questionnaire, differing in the order of questions 1 and 2, were initially used in the study.The correct order of questions in The Diabetes Distress Scale is as follows:Question 1: Feeling that diabetes taking up too much of my mental and physical energy every day.Question 2: Feeling that my doctor doesn’t know enough about diabetes and diabetes careThe editorial board regrets this error. The original version of the article has been replaced.

  • Advantages and limitations of metformin in gestational diabetes

    by V.A. Uchamprina, M.F. Kalashnikova, E.I. Bobrova, M.G. Pavlova, F.KH. Dzgoeva, Yu.P. Sych, P.A. Kazaryan, E.V. Fedorova, V.V. Fadeev

    The role of metformin in the treatment of gestational diabetes (GD) remains controversial. It has long been used in clinical trials, and there is now sufficient data on the absence of teratogenic effects of the medication and its high safety profile. This has allowed metformin to be included as a second- or even first-line therapy in many updated international guidelines in recent years. However, in Russia, the use of metformin in pregnant women with GD is still not recommended, according to the approved clinical guidelines for the treatment of GD in 2024. At the same time, the Federal Service for Supervision of Healthcare of the Russian Federation has updated the instructions for the medical use of metformin and removed “pregnancy” from the “Contraindications” section. It also states that metformin can be used in cases of extreme necessity, when the expected benefit of therapy for the mother outweighs the possible risk to the fetus. This literature review analyzes data on the advantages and disadvantages of metformin in GD and proposes criteria for selecting candidates for this therapy in further studies. Key words: metformin, gestational diabetes (GD), pregnancy

  • Open Access

    Adaptation of The Diabetes Distress Scale on a Russian-speaking sample of patients with type 1 and type 2 diabetes mellitus

    by N. V. Likhodey, V. E. Epishin, M. F. Kalashnikova, A. M. Kaurova, M. V. Tulupova, Y. P. Sych, I. B. Bondareva

    BACKGROUND: Diabetes distress (DD) is the negative emotional or affective experience resulting from living with diabetes. DD is a negative predictor of blood glucose control and quality of life, and may lead to decreased adherence to treatment. To diagnose DD, questionnaires are used to screen the emotional state and psychosocial aspects. In the study, linguistic, cultural adaptation and assessment of the psychometric properties of the Russian version of the questionnaire “The Diabetes Distress Scale” were conducted among patients suffering from T1DM and T2DM.Patients with diabetes mellitus (DM) have diabetic distress as one of the most common mental disorders along with depression. Depression and diabetic distress increase the risk of death in diabetes, negatively affect treatment adherence and self-monitoring of glycemia. Identification of these conditions among patients with T1DM and T2DM can contribute to their timely correction.AIM: To carry out linguistic and cultural adaptation of the questionnaire “The Diabetes Distress Scale” and evaluate the psychometric properties of the Russian version of the DDS questionnaire on a Russian-speaking sample of patients with T1DM and T2DM.MATERIALS AND METHODS: A study was conducted on a sample of 198 patients with T1DM and T2DM; data was collected on the use of the Russian version was collected DDS scales, as well as the EQ-5D-5L (European Quality of Life Questionnaire), SPANE (Positive and Negative Experiences Scale) and HADS (Hospital Anxiety and Depression Scale) scales. The last three scales were used to assess the convergent validity of the adapted questionnaire. Reliability of the DDS questionnaire was assessed using Cronbach’s α coefficient of internal consistency and participant retest after 1–4 months.RESULTS: The factor structure of The Diabetes Distress Scale questionnaire is fully reproduced when all 17 questions are included (measurement model fit indicators: CFI=0.981, RMSEA=0.055, TLI=0.967). The internal consistency of the subscales (α ϵ [0.836; 0.874]) and the questionnaire as a whole (α=0.948) is assessed as high. Significant correlations of the adapted methodology and its subscales with the scales of the EQ-5D-5L, SPANE, HADS questionnaires were obtained, the closest connections (Rho ϵ [0.370; 0.437], pCONCLUSION: The Russian version of the DDS questionnaire has good psychometric properties. It is a valid and reliable tool for assessing diabetes distress among patients with T1DM and T2DM and can be recommended for use in clinical practice for timely diagnosing depression and DD.


  • Open Access

    Endocrine disorders in Kearns-Sayre syndrome with different severity of symptoms: two case reports and a literature review

    by Ilya I. Amergoolov, Yulia I. Khruleva, Maria G. Pavlova, Natalia V. Likhodey, Abu M. Sulaev, Elena V. Surkova, Yulia P. Sych, Marina F. Kalashnikova, Anna S. Arustamyan, Gratsinna A. Martirosyan, et al.

    Kearns-Sayre Syndrome (KSS) is a variant of mitochondrial disorder caused by a Mitochondrial Deoxyribonucleic Acid (mtDNA) deletion. Clinical manifestations of KSS can include different organ and system involvement. Different organ malfunctions, more often cardiac dysfunction, can lead to death. No effective treatment of this condition exists to date. Here, we report two patients with KSS. Female patient with a large-scale deletion of 7,020 base pairs (bp) suffered from hypogonadism, diabetes mellitus with fluctuating glucose levels, and had poor general health. A male patient with a common 4,977 bp deletion did not have diabetes mellitus but had impaired glucose tolerance. He also had a higher level of general health than our female patient. Both patients had reduced Bone Mineral Density (BMD). In female patients, calcium and vitamin D supplementation combined with metabolic therapy and nutritional drink supplements helped increase BMD (up to 32% in L1-L4). Comparing these two patients suggests that the larger the mtDNA deletion is, the more severe the course of the disease is. Not only does the size of the mtDNA deletion probably determine the severity of the disease, but also such factors as mtDNA heteroplasmy level, presence of mtDNA duplications, and pleioplasmy. Moreover, continuous nonconsecutive metabolic therapy and nutritional supplements are helpful in the prevention of deterioration of symptoms and general health.


  • Open Access

    Differential diagnosis of amiodarone-induced thyrotoxicosis in a patient with atrial fibrillation and agranulocytosis on the background of thyrostatic therapy. Case report

    by Kristina Yu. Zherebchikova, Dmitry S. Bubnov, Alexandra S. Ermolaeva, Madina O. Soltakhanova, Yulia P. Sych, Marat V. Ezhov, Valentin V. Fadeev

    Atrial fibrillation is the most common heart rhythm disorder in patients with chronic heart failure. One of the most effective antiarrhythmic drugs for the treatment and prevention of a wide range of supraventricular and ventricular tachyarrhythmia is amiodarone. In the group of patients with paroxysmal atrial fibrillation and low left ventricular ejection fraction, it is the drug of choice when conducting a „rhythm control“ strategy. Patients receiving amiodarone often develop an adverse event – amiodarone-induced thyrotoxicosis, which exacerbates the course of cardiovascular pathology. In this article, we consider a clinical case of amiodarone-induced thyrotoxicosis in a 30-year-old patient with dilated cardiomyopathy and agranulocytosis that developed against the background of thyrostatic therapy.